Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced HCC patients

A new research paper titled "Plasma growth hormone is a potential biomarker of response to atezolizumab and bevacizumab in advanced hepatocellular carcinoma patients" has been published in Oncotarget.